Adenoviral virotherapy for malignant brain tumors.
Glioblastoma multiforme is the most common form of primary brain cancer. In the past decade, virotherapy of tumors has gained credence, particularly in glioma management, as these tumors are not completely resectable and tend to micro-metastasize. Adenoviral vectors have an advantage over other viral vectors in that they are relatively non-toxic and do not integrate in the genome. However, the lack of coxsackie and adenovirus receptors on surface of gliomas provides for inefficient transduction of wild-type adenoviral vectors in these tumors. By targeting receptors that are overexpressed in gliomas, modified adenoviral constructs have been shown to efficiently infect glioma cells. In addition, by taking advantage of tumor-specific promoter elements, oncolytic adenoviral vectors offer the promise of selective tumor-specific replication. This dual targeting strategy has enabled specificity in both laboratory and pre-clinical settings. This review examines current trends in adenoviral virotherapy of gliomas, with an emphasis on targeting modalities and future clinical applications.
Nandi
Suvobroto
S
The University of Chicago, The Brain Tumor Center, Chicago, Illinois 60637, USA.
Lesniak
Maciej S
MS
D000256:Adenoviridae / Q000502:physiology; D017209:Apoptosis; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D005909:Glioblastoma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D050130:Oncolytic Virotherapy; D014779:Virus Replication